All articles tagged with #obesity treatments
Novo Nordisk has increased its bid to acquire Metsera to up to $10 billion, surpassing Pfizer's recent offer of $8.1 billion, escalating the takeover battle for the obesity-focused biotech, which has significant implications for the weight-loss pharmaceutical market.
The market for blockbuster weight loss drugs is rapidly growing, dominated by Eli Lilly and Novo Nordisk, with Eli Lilly currently leading due to superior efficacy and safety. Competition is intensifying with new drugs, including oral pills, and challenges such as insurance coverage, drug pricing, and copycat versions persist. Future growth depends on regulatory decisions, new drug developments, and market access improvements.
Eli Lilly's obesity and diabetes drugs Mounjaro and Zepbound generated over $10 billion in Q3, fueling a booming market and a bidding war, with Novo Nordisk planning to acquire Metsera in a deal potentially worth up to $9 billion, highlighting intense competition in the GLP-1 receptor agonist space.
Pfizer is expanding into the obesity treatment market with a nearly $5 billion acquisition of development-stage drugmaker Metsera, aiming to enhance its pipeline amid rising demand for obesity therapies and potential price competition.
Medicare will now cover certain weight loss drugs if they are approved for an additional health benefit, opening the door for broader coverage of popular medications like Novo Nordisk's Wegovy, which is now approved for heart health. This move comes as demand for weight loss treatments has surged despite limited insurance coverage. The new guidance allows Medicare Part D plans to cover obesity treatments with FDA approval for an added health benefit, potentially including future coverage for other weight loss medications being studied for conditions like fatty liver disease and sleep apnea.
Eli Lilly shares reached a record high after completing two acquisitions, expanding its reach into potential diabetes and obesity treatments. The deals include the purchase of Versanis Bio, which could be valued up to $1.925 billion, and Sigilon Therapeutics, with a potential transaction worth about $309.6 million. Eli Lilly's shares have risen nearly 50% this year.
Only about one-third of patients prescribed weight-loss drugs like Novo Nordisk's Wegovy were still taking them a year later, according to an analysis of U.S. pharmacy claims. The study found that total healthcare costs for the group rose sharply, with the annual cost of care increasing by 59% on average after starting the medication. The analysis highlights the need for better targeting of these drugs to patients who are likely to benefit from them, as the high costs may not lead to long-term health improvements.